Pages that link to "Q39852544"
Jump to navigation
Jump to search
The following pages link to The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. (Q39852544):
Displaying 50 items.
- Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting (Q26742012) (← links)
- Primary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancer (Q27009148) (← links)
- Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein (Q28731516) (← links)
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial (Q33614005) (← links)
- The role of regulatory T cells in cancer (Q33631986) (← links)
- FOXP3 and GARP (LRRC32): the master and its minion (Q33673969) (← links)
- MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients (Q34034978) (← links)
- Perspectives on Regulatory T Cell Therapies (Q34263542) (← links)
- A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. (Q34461203) (← links)
- Profound tumor-specific Th2 bias in patients with malignant glioma (Q34491734) (← links)
- The present status and future prospects of peptide-based cancer vaccines (Q34528638) (← links)
- Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade (Q34645401) (← links)
- Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma (Q35218562) (← links)
- Immunosuppressive tumor microenvironment in cervical cancer patients (Q35603131) (← links)
- Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma (Q36075245) (← links)
- Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. (Q36292634) (← links)
- Epigenetic biomarkers of T-cells in human glioma. (Q36484129) (← links)
- Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E. (Q36561664) (← links)
- Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance (Q37028767) (← links)
- Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy (Q37100031) (← links)
- Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines (Q37137360) (← links)
- Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine (Q37297514) (← links)
- Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. (Q37762274) (← links)
- Tumor vaccines and beyond (Q37808467) (← links)
- Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? (Q37873379) (← links)
- MAGED1: molecular insights and clinical implications (Q37879671) (← links)
- Melanoma vaccines: developments over the past 10 years. (Q37892595) (← links)
- Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? (Q37973820) (← links)
- Targeting regulatory T cells (Q37983467) (← links)
- Monitoring regulatory immune responses in tumor immunotherapy clinical trials (Q38105081) (← links)
- Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies (Q38196935) (← links)
- PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines (Q38264346) (← links)
- Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells (Q38603362) (← links)
- Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy (Q38949770) (← links)
- Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples. (Q39535112) (← links)
- The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides (Q39725034) (← links)
- MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells (Q40987678) (← links)
- FOXP3 Expression in GARP-Transduced Helper T Cells Is Not Associated with FOXP3 TSDR Demethylation (Q42181657) (← links)
- An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. (Q42427592) (← links)
- Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer (Q42571627) (← links)
- AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial (Q44644226) (← links)
- Role of GARP in the activation of latent TGF-β1. (Q47969786) (← links)
- Therapeutic blockade of Foxp3 in experimental breast cancer models. (Q48325267) (← links)
- Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients. (Q51093928) (← links)
- Regulatory T cells, as a target in anticancer immunotherapy. (Q52764469) (← links)
- Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. (Q54427491) (← links)
- Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma (Q57571845) (← links)
- ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity (Q64279107) (← links)
- T cell pathology in skin inflammation. (Q64890943) (← links)
- Regulatory T cells in cancer (Q84073243) (← links)